

79% of migraine patients reported “no side effects” to be an important attribute of migraine therapy.¹

Maria, 23

“I’m concerned about the side effects of prescription drugs, especially since I’m currently using oral contraceptives.”

Occupation


- Full-time graduate student

Migraine history

- Suffers migraines during and outside her period
- Misses at least 1 day of classes each month because of migraines
- Would like to use prescription medication for migraines, but is concerned about interactions with oral contraceptives

Current migraine treatment

- Uses over-the-counter drugs, but is not satisfied with the relief she’s getting for migraines around her period



NAME Maria Martinez						
SUNDAY	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY
		X		X		
					X	

Migraines around a woman’s period are reported to occur with greater severity, persist longer, and may be more resistant to treatment.²⁻⁴

What is an appropriate prescription option for someone who is concerned about drug interactions and side effects?

References: 1. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? *Headache*. 1999;39(suppl 2):S20-S26. 2. Granella F, Sances G, Allais G, et al. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. *Cephalalgia*. 2004;24(9):707-716. 3. MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. *Neurology*. 2004;63(2):351-353. 4. Couturier EGM, Bomhof MAM, Knuistringh Neven A, van Duijn NP. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. *Cephalalgia*. 2003;23(4):302-308.

FROVA[®] is generally well tolerated

Adverse events profile similar to that of placebo in clinical trials¹

Most common adverse reactions ^a	FROVA (n=1,554)	Placebo (n=838)
Dizziness	8%	5%
Fatigue	5%	2%
Paresthesia	4%	2%
Flushing	4%	2%
Headache	4%	3%
Dry mouth	3%	1%
Hot or cold sensation	3%	2%
Skeletal pain	3%	2%
Chest pain	2%	1%
Dyspepsia	2%	1%

Only 1% of patients withdrew due to adverse events.

^aIncidence $\geq 2\%$ and greater than placebo among patients in 4 placebo-controlled trials.

- **No known clinically significant drug-drug interactions, including oral contraceptives¹**
- **In vitro studies show that FROVA is not an inhibitor of human monoamine oxidase (MAO) enzymes or cytochrome P-450¹**

FROVA is indicated for the acute treatment of migraine attacks with or without aura in adults where a clear diagnosis of migraine has been established. FROVA is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine.

Important Safety Information

The safety and effectiveness of FROVA have not been established for cluster headache, which is present in an older, predominantly male population. FROVA should not be given to patients with cerebrovascular syndromes, peripheral vascular disease, uncontrolled hypertension, ischemic heart disease, or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal's variant angina or other significant underlying cardiovascular disease. FROVA should not be given to patients within whom unrecognized coronary artery disease is predicted by the presence of risk factors without a prior cardiovascular evaluation. The development of a potentially life-threatening serotonin syndrome may occur with triptans, including FROVA treatment, particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs). If concomitant treatment with FROVA and an SSRI or SNRI is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. The most common side effects associated with use of FROVA are dizziness, fatigue, paresthesia, flushing, headache, dry mouth, hot or cold sensation, skeletal pain, chest pain, and dyspepsia.

Reference: 1. FROVA [package insert], Chadds Ford, PA: Endo Pharmaceuticals Inc; 2007.

FROVA first
for female migraine sufferers



Frova[®]
frovatriptan succinate
2.5mg Tablets

Please see enclosed full Prescribing Information.

R_x only

FROVA[®] is a registered trademark of Vernalis Development Limited.



CHADDS FORD, PENNSYLVANIA 19317

© 2008 Endo Pharmaceuticals. All Rights Reserved. FR-0216/MARCH 2008 www.frova.com 1-800-462-ENDO

visit www.frova.com